Previous 10 | Next 10 |
The United States Department of Veteran Affairs (VA) has expressed that it is willing to consider the use of psychedelics in post-traumatic stress disorder (PTSD) treatment. In a statement issued to KDKA-TV Investigates, the agency said that it is open to the use of hallucinogenics to treat PTS...
Researchers have found that there may be a “clear association” between psychedelic use and embracing alternative viewpoints. Intent on determining whether exposure to psychedelics made people more likely to affirm alternative views, the research team provided a Conspiracy Mentality...
2023-11-05 01:03:52 ET Summary In August 2023 COMPASS Pathways announced a major private placement that initially eased concerns regarding the group’s cash runway. A sharp fall in the COMPASS Pathways share price since mid-September 2023 has put the majority of the private ...
2023-11-04 11:51:04 ET COMPASS Pathways plc (CMPS) Q3 2023 Results Conference Call November 02, 2023 08:00 AM ET Company Participants Stephen Schultz - SVP, IR Kabir Nath - CEO Mary-Rose Hughes - Interim CFO Dr. Guy Goodwin - Chief Medical Officer Confe...
2023-11-03 11:39:36 ET Image source: The Motley Fool. Compass Pathways Plc (NASDAQ: CMPS) Q3 2023 Earnings Call Nov 02, 2023 , 8:00 a.m. ET Operator Continue reading For further details see: Compass Pathways Plc (CMPS) Q3 2023 Earnings Call Tr...
2023-11-02 08:09:11 ET More on COMPASS Pathways ADS Compass Pathways: Debt Deal Secured, Cash Runway Extended COMPASS Pathways plc (CMPS) Q2 2023 Earnings Call Transcript Psychedelics research amendments advance in House committee With ecstasy a potential PTS...
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
LONDON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the third quarter 2023 and provided an ...
COMPASS Pathways Plc (CMPS) is expected to report $-0.5 for Q3 2023
Researchers from Sorbonne University have found that ketamine can reduce depression symptoms in patients with treatment-resistant depression (TRD) just four hours after infusion. Compared to healthy controls, patients with TRD reported feeling more optimistic a few hours after ketamine infusion...
News, Short Squeeze, Breakout and More Instantly...
LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2024 ending June 30, 2024, a...
New research has determined that psilocybin may impact the brain. Psilocybin is the primary psychoactive compound found in hallucinogenic mushrooms. When ingested, it distorts an individual’s perception of time, among other changes. Researchers have observed that in animals, psilocyb...